Last updated 2026-07-20
- Acquired by Bristol Myers Squibb for $74B, Nov 2019
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Celgene Corporation (Japan) is the Japanese arm of Celgene Corporation, a biopharmaceutical company that discovers, develops, and commercializes therapies for cancer, immunology, and severe inflammatory diseases. The Japanese entity is involved in the development, import, manufacture, and sales of ethical pharmaceuticals. Celgene Corporation was acquired by Bristol Myers Squibb (BMS) in 2019, and its Japan operations integrated with BMS Japan in 2021.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is Celgene Corporation(Japan)'s primary investment focus?
- Celgene Corporation(Japan) primarily invests in the Health Tech & Life Sciences sector, with its sole recorded portfolio company, Biond Biologics, operating in this area.
- Can you name a notable company in Celgene Corporation(Japan)'s portfolio?
- A notable company in Celgene Corporation(Japan)'s portfolio is Biond Biologics, which develops immunotherapies for cancer and auto-immune diseases.
- When did Celgene Corporation(Japan) make its most recent investment?
- Celgene Corporation(Japan) made its most recent investment in January 2019, which was its only recorded investment.
- What stage of funding does Celgene Corporation(Japan) typically participate in?
- Celgene Corporation(Japan) has participated in B-round funding, as seen with its investment in Biond Biologics.
- What was the investment amount for Biond Biologics?
- Biond Biologics raised $37M in its Series C funding round, in which Celgene Corporation(Japan) participated.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2016 |
|---|
Acquisitions & public offerings
Acquired by Bristol Myers Squibb 2019-11 $74.0B